Log In
Print
BCIQ
Print
Print this Print this
 

RX-3117

  Manage Alerts
Collapse Summary General Information
Company Rexahn Pharmaceuticals Inc.
DescriptionNext-generation oral nucleoside analog that is activated by uridine cytidine kinase and inhibits DNA and RNA synthesis and mediates the down-regulation of DNA (cytosine-5-)-methyltransferase 1 (DNMT1)
Molecular Target DNA methyltransferase
Mechanism of ActionDNA methyltransferase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today